Cash From Financing Activities - Calithera Biosciences Inc (F:2CB) - Alpha Spread
C

Calithera Biosciences Inc
F:2CB

Watchlist Manager
Calithera Biosciences Inc
F:2CB
Watchlist
Price: 3.86 EUR -2.53% Market Closed
Market Cap: 1m EUR
Have any thoughts about
Calithera Biosciences Inc?
Write Note

Calithera Biosciences Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Calithera Biosciences Inc
Cash from Financing Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
C
Calithera Biosciences Inc
F:2CB
Cash from Financing Activities
$9.7m
CAGR 3-Years
-54%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.4B
CAGR 3-Years
46%
CAGR 5-Years
25%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.9B
CAGR 3-Years
N/A
CAGR 5-Years
5%
CAGR 10-Years
-38%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$3.6B
CAGR 3-Years
29%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1B
CAGR 3-Years
-10%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.3B
CAGR 3-Years
-93%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Calithera Biosciences Inc's Cash from Financing Activities?
Cash from Financing Activities
9.7m USD

Based on the financial report for Dec 31, 2022, Calithera Biosciences Inc's Cash from Financing Activities amounts to 9.7m USD.

What is Calithera Biosciences Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-40%

Over the last year, the Cash from Financing Activities growth was -9%. The average annual Cash from Financing Activities growth rates for Calithera Biosciences Inc have been -54% over the past three years , -40% over the past five years .

Back to Top